These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35116365)

  • 1. Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis.
    Li S; Wang T; Lai W; Zhang M; Cheng B; Wang S; Tong G
    Transl Cancer Res; 2021 Dec; 10(12):5150-5158. PubMed ID: 35116365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review.
    Guzman-Prado Y; Ben Shimol J; Samson O
    Cancer Immunol Immunother; 2021 Oct; 70(10):2771-2780. PubMed ID: 33625531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
    Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.
    Xu H; Xu X; Ge W; Lei J; Cao D
    Ther Adv Med Oncol; 2020; 12():1758835920980546. PubMed ID: 33425028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis.
    Pei WG; Chen WZ; Wu YK; Tan SX; Jie ZG
    World J Gastrointest Oncol; 2023 Feb; 15(2):352-367. PubMed ID: 36908315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Suazo-Zepeda E; Bokern M; Vinke PC; Hiltermann TJN; de Bock GH; Sidorenkov G
    Cancer Immunol Immunother; 2021 Nov; 70(11):3069-3080. PubMed ID: 34195862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.
    Guzman-Prado Y; Ben Shimol J; Samson O
    Cancer Immunol Immunother; 2021 Jan; 70(1):89-100. PubMed ID: 32648164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
    Fan Y; Xie W; Huang H; Wang Y; Li G; Geng Y; Hao Y; Zhang Z
    Front Oncol; 2021; 11():633032. PubMed ID: 33912454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis.
    Zhang S; Zhou Z; Wang L; Li M; Zhang F; Zeng X
    Ther Adv Chronic Dis; 2021; 12():2040622320976996. PubMed ID: 33633822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors.
    Zhong L; Wu Q; Chen F; Liu J; Xie X
    Cancer Immunol Immunother; 2021 Sep; 70(9):2559-2576. PubMed ID: 33576872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.
    Yamaguchi A; Saito Y; Okamoto K; Narumi K; Furugen A; Takekuma Y; Sugawara M; Kobayashi M
    Support Care Cancer; 2021 Dec; 29(12):7747-7753. PubMed ID: 34164739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.
    Feng Y; Guo K; Jin H; Jiang J; Wang M; Lin S
    Front Immunol; 2023; 14():1269067. PubMed ID: 38250059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis.
    Wang D; Chen C; Gu Y; Lu W; Zhan P; Liu H; Lv T; Song Y; Zhang F
    Front Oncol; 2021; 11():631949. PubMed ID: 33732650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.